Asymptomatic Myeloma Prognosis

Asymptomatic (smoldering) myeloma carries a variable prognosis but typically progresses to symptomatic myeloma at a rate of about 10% per year in the first 5 years.

Bone marrow plasmacytosis
< 10%+1≥ 10%+10
Serum monoclonal protein, g/dl
< 3+1≥ 3+5

Indications for Use

Used for adults with asymptomatic (smoldering) myeloma to estimate risk of progression and guide follow‑up intensity. Most useful when incorporating M‑protein, bone‑marrow plasma cells, and free light‑chain ratio, which strongly predict progression 1. Supports decisions on observation frequency and identifying high‑risk patients who may merit clinical trial enrollment rather than routine therapy 2.

Insights & Cautions

Progression risk hinges on M‑protein ≥2 g/dL, BM plasma cells ≥20%, and FLC ratio ≥20, with 2–3 factors yielding ~46% 2‑year progression risk (Mayo 20/2/20) 1 [Level II evidence]. Additional adverse markers include PET‑CT focal lesions (~58–75% 2‑year risk) 2 [Level II evidence] and high‑risk cytogenetics (del17p, t(4;14), +1q) 3 [Level II evidence]. Caution: risk models vary, discordance is common, and overtreatment remains a concern.